Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective

Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection

Dorte Lybaek A B and Carsten Schade Larsen A
+ Author Affiliations
- Author Affiliations

A Department of Infectious Diseases, Skejby Hospital, University Hospital of Aarhus, DK-8200 Aarhus N, Denmark.

B Corresponding author. Email:

Sexual Health 5(1) 69-71
Submitted: 2 November 2007  Accepted: 22 January 2008   Published: 22 February 2008


A previously healthy young man experienced several episodes of syncope while being treated with tenofovir, emtricitabine and nevirapine initiated during primary HIV-1 infection. Symptoms disappeared after discontinuation of antiretroviral therapy and we suggest that syncope may be a side effect to one of the three antiretroviral drugs that has not been described previously.


[1] Kinloch-de Loes S. Treatment of acute HIV-1 infection: is it coming of age? J Infect Dis 2006; 194 721–4.
CrossRef | PubMed |

[2] Gerstoft J , Mathiesen L , Lundgren JD , Nielsen HI , Pedersen C , Obel N , et al Retningslinier for HIV-behandling; 2006. Available online at: [verified February 2008].

[3] van Leth F,  Phanuphak P,  Ruxrungtham K,  Baraldi E,  Miller S,  Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363 1253–63.
CrossRef | PubMed |

[4] Adkins JC,  Noble S. Efavirenz. Drugs 1998; 56 1055–64.
CrossRef | PubMed |

[5] Frampton JE,  Perry CM. Emtricitabine: a review of its use in the management of HIV infection.  Drugs 2005; 65 1427–48.
CrossRef | PubMed |

[6] Saag MS,  Chan P,  Raffi F,  Wolff M,  Pearce D,  Molina JM, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients. JAMA 2004; 292 180–90.
CrossRef | PubMed |

[7] Mira JA,  Lozano F,  Santos J,  Ramayo E,  Terrón A,  Palacios R, et al. Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment. Antivir Ther 2004; 9 511–17.
PubMed |

[8] Strub C,  Kaufmann GR,  Flepp. M,  Egger M,  Kahlert C,  Cavassini M, et al. Gynaecomastia and antiretroviral therapy. AIDS 2004; 18 1347–9.
CrossRef | PubMed |

[9] Smith DE,  Walker BD,  Cooper DA,  Rosenberg ES,  Kaldor JM. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 2004; 18 709–18.
CrossRef | PubMed |

[10] Hecht FM,  Wang L,  Collier A,  Little S,  Markowitz M,  Margolick J, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006; 194 725–33.
CrossRef | PubMed |

[11] Streeck H,  Jessen H,  Alter G,  Teigen N,  Waring MT,  Jessen A, et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 2006; 194 734–9.
CrossRef | PubMed |

[12] Steingrover R , Bezemer D , Fernandez Garcia E , Kroon F , de Wolf F , Prins M , et al Early treatment of primary HIV-1 infection lowers the viral set point. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles, CA, USA. CROI 2007. Available online at: [verified February 2008]. Abstract 124LB.

[13] Koegl C , Wolf E , Jessen H , Schewe K , Rausch M , Goelz J , et al No benefit from early treatment in primary HIV-infection? 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles, CA, USA. CROI 2007. Available online at: [verified February 2008]. Abstract 125LB.

[14] Hammer SM,  Saag MS,  Schechter M,  Montaner JSG,  Schooley RT,  Jacobsen DM, et al. Treatment for adult HIV infection. 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296 251–65.
CrossRef |

[15] Bartlett JG , Lane HC , Pau AK , Anderson J , Baker AC , Bozzette SA , et al Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV; October 2006: 1–121. Department Health and Human Services.

[16] Gazzard B on behalf of the BHIVA writing Committee. British HIV association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7 487–503.
CrossRef | PubMed |

Rent Article (via Deepdyve) Export Citation Cited By (3)